HSV 2 Formulation 2 (Sanofi)

**HSV 2 Formulation 2** was a trial-specific, intramuscular investigational therapeutic HSV-2 vaccine formulation evaluated by Sanofi in adults with recurrent genital herpes. It was one of six masked formulation labels used in the terminated HSV15 study, which assessed safety and effects on genital HSV DNA shedding and recurrence after a two-dose schedule. Public trial materials do not identify the precise antigen composition corresponding specifically to Formulation 2; the broader program evaluated formulations involving the replication-defective HSV529 vaccine and the recombinant-protein vaccine G103, with GLA-SE adjuvant used in program formulations. ([ctv.veeva.com](https://ctv.veeva.com/study/safety-and-efficacy-of-4-investigational-hsv-2-vaccines-in-adults-with-recurrent-genital-herpes-caus))